NOVARTIS

Ilaris - Safety profile - HCP

Prescribing information

Image

Image

ILARIS® (canakinumab) safety profile

Indications[1]

Periodic fever syndromes
ILARIS is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:

- Cryopyrin-associated periodic syndromes (CAPS), including:
    - Muckle-Wells syndrome (MWS)

    - Neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurological, cutaneous, articular syndrome (CINCA)

    - Severe forms of familial cold autoinflammatory syndrome (FCAS)/familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash

- Tumour necrosis factor receptor associated periodic syndrome (TRAPS)

- Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)

- Familial Mediterranean Fever (FMF)

    - ILARIS should be given in combination with colchicine, if appropriate

Still’s disease
ILARIS is indicated in patients who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids, for the treatment of active Still’s disease, including:

- Adult-onset Still’s disease (AOSD)

- Systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older

- ILARIS can be given as monotherapy or in combination with methotrexate

Gouty arthritis
ILARIS is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.

ILARIS safety profile in periodic fever syndromes (PFS)

FMF, HIDS/MKD, TRAPS and CAPS

Find out more

ILARIS safety profile in Still’s disease

AOSD and SJIA

Find out more

AOSD, adult-onset Still’s disease; CAPS, cryopyrin-associated periodic syndromes; CINCA, chronic infantile neurological, cutaneous, articular syndrome; FCAS, familial cold autoinflammatory syndrome; FCU, familial cold urticaria; FMF, familial Mediterranean fever; HIDS, hyperimmunoglobulin D syndrome; MKD, mevalonate kinase deficiency; MWS, Muckle-Wells syndrome; NOMID, neonatal-onset multisystem inflammatory disease; NSAID, non-steroidal anti-inflammatory drug; SJIA, systemic juvenile idiopathic arthritis; TRAPS, tumour necrosis factor receptor-associated periodic syndrome.

Reference

1. ILARIS® (canakinumab) Summary of Product Characteristics.

Safety profile in PFS

Safety profile in PFS

See more details

Hide details

UK | March 2025 | FA-11324189

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Source URL:
https://www.pro.novartis.com/uk-en/medicines/immunology/ilaris/safety-profile